Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13973473 | 0.85 | KMT2A (0.66) | KMT2APOLBMEN1SMN1; SMN2KDM1A | |
| SCHEMBL27329722 | 0.80 | NCEH1 (0.62) | KMT2APOLBMEN1MAPT | |
| SCHEMBL12530633 | 0.79 | KCNT1 (0.56) | KMT2AMEN1SLC2A1MAPT | |
| SCHEMBL29227225 | 0.79 | LMNA (0.69) | KMT2APOLBMEN1SMN1; SMN2SLC2A1 | |
| SCHEMBL9289234 | 0.79 | NCEH1 (0.57) | KMT2APOLBMEN1MAPT | |
| SCHEMBL1254854 | 0.79 | KMT2A (0.61) | KMT2APOLBMEN1SMN1; SMN2KDM1A | |
| SCHEMBL14543901 | 0.79 | ABCB1 (0.45) | KMT2APOLBMEN1SMN1; SMN2SLC2A1 | |
| SCHEMBL28010488 | 0.78 | NCEH1 (0.56) | KMT2APOLBMEN1MAPT | |
| Hydrochloric Acid SCHEMBL3292392 | 0.77 | ABCB1 (0.44) | KMT2APOLBMEN1SMN1; SMN2SLC2A1 | |
| SCHEMBL28387488 | 0.77 | NCEH1 (0.60) | KMT2APOLBMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KMT2A 625/4885POLB 1663/4885MEN1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.